Add to balance / Manage account | User: | Log out |
Prospect News home > News index > List of issuers H > Headlines for Hollis-Eden Pharmaceuticals, Inc. > News item |
Jefferies stops Hollis-Eden coverage at hold
Jefferies & Co., Inc. analyst Adam Walsh is dropping coverage of Hollis-Eden Pharmaceuticals, Inc. with a last rating of hold and a 12- to 18-month price target of $5.50 to focus on other therapeutic areas within the biotechnology sector. Shares of the San Diego, Calif., pharmaceutical company were up 3 cents, or 0.43%, at $7.08. (Nasdaq: HEPH)
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.